News

Oxford Brain Diagnostics looks for collaboration partners for neurodegeneration

Oxford Brain Diagnostics looks for collaboration partners for neurodegeneration
Collaboration, Dementia
Member News

We are on a mission to change the way the world thinks about brain health. Our novel technology assesses brain health based on changes in the cellular structure. We enable more efficient drug development and personalised patient care.

Oxford Brain Diagnostics are looking for interested clinicians dealing with dementia who would like to learn about a  new approach to MRI-based diagnosis, which can predict transition from MCI to Alzheimer’s Disease, and has  received FDA breakthrough device designation (neurologists, psychiatrists, radiologists, focus on US). 

We are developing a new software tool for the interpretation of MRI images, pulling together current volumetric  methods (cortical volume, cortical thickness, hippocampal measures) with our new measure which analyses changes  in the brain at a cellular level. Our goal is to bring an innovative diagnostics tool which will positively enable better  patient care, more certainty in diagnosis, differential diagnosis of dementia, and the possibility to accurately track  decline (www.oxfordbraindiagnostics.com) 

Some recent papers published  

Also see https://oxfordbraindiagnostics.com/06-publications.html 

Cortical diffusivity investigation in posterior cortical atrophy and typical Alzheimer’s disease. Mario Torso (et al) – Journal of Neurology (2020) Journal of Neurology 

Using diffusion tensor imaging to detect cortical changes in fronto-temporal dementia subtypes. M. Torso (et al) – Scientific Reports, A Nature research Journal 

Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes  following blast exposure. Dara L. Dickstein (et al) – Molecular Psychiatry  

Relating diffusion tensor imaging measurements to microstructural quantities in the cerebral cortex in multiple  sclerosis. Rebecca McKavanagh (et al) – Human Brain Mapping Journal

Discover more about Oxford Brain Diagnostics:

Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company’s patented Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.

NEWS​

Related News

A Shift to Value-Based Procurement in Digital Health Solutions

16 May 2024
The shift towards value-based procurement in healthcare, focusing on long-term effectiveness and patient outcomes, rather than initial costs. The Dire...

Launching Moxiam+: the digital companion for an active and independent senior lifestyle

16 May 2024
Embark on a journey with Sweden-based Moxiam, the vanguard of digital health innovation dedicated to enriching the lives of seniors. Moxiam leverages ...

Romania – Transylvania Digital Health Ecosystem by FreshBlood is ECHAlliance Ecosystem of the Month – May

15 May 2024
This month we are featuring our Transylvania Digital Health Ecosystem by FreshBlood from Romania as our Ecosystem of the Month.

Revolutionising healthcare: how digitisation will transform care in the next 5 years

14 May 2024
On November 5-6, at the 6th Digital Health Society Summit, we'll explore how digitalisation is set to revolutionise healthcare in the next 5 years.

Dermatology from a broader view: mind-body connection

14 May 2024
Mind-body connection is a term that describes a connection between the mental layer and the body and in the case of a skin disease, the skin. Mind-bod...

CARE4DIABETES (C4D): Reducing the burden of non-communicable diseases

14 May 2024
Non-communicable diseases (NCDs) are responsible for 80% of the disease burden in the EU countries and the leading causes of avoidable premature death...

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *